Martin MacLean

Partner at Mathys & Squire LLP

Martin MacLean has over 20 years of IP experience with particular expertise in patent portfolio management for corporates and government. He is top ranked in Band 1 of Chambers UK, where he is described as “a biochemistry and biotech expert responsible for prosecuting often revolutionary and highly valuable patent portfolios”, as well as being “highly responsive and creative” (Chambers UK 2020). The 2020 edition of The Legal 500 recommends Mr MacLean for being “a real guru in the healthcare and pharmaceutical field”, bringing “his experience to bear in not only giving very wise legal advice, but also setting things in a commercial context”. He is also ranked in the latest edition of the IAM Strategy 300.

Mr MacLean has conducted over 100 European Patent Office hearings, with a success rate of approximately 90%. He has a strong biotech background (PhD in microbial engineering from Warwick University), and specialises in technologies such as the protein therapeutics, antibodies, vaccines, expression systems, diagnostic assays and ‘green’ agrochemicals.

Mr MacLean has extensive high-value (over £10 million) M&A due diligence experience, which he is able to combine with the above core aspects of IP management, to provide valuable advice that is both informed and balanced.

Firm details

Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG
United Kingdom

Contact details

See firm profile